IOM Undertakes Study of Cancer and Minorities
Intense lobbying by the Intercultural Cancer Council (ICC) resulted in Congress providing $600,000 for a study on "the status of research into cancer among minorities and the medically underserved at the National Institutes of Health." The study will be carried out by an advisory committee expected to be established in early 1997 by the Institute of Medicine. The committee will examine a laundry list of issues, some of them already the subject of analysis by the new NCI office of special populations headed by Otis Brawley, md, an oncologist. Brawley says he is trying to come up with a research agenda that gets beyond some of the myths that have politicized the cancer field. For example, he notes that contrary to conventional wisdom, blacks in many cases form a disproportionately high percentage of participants in cancer treatment trials. Lovell Jones, phd, director of experimental gynecology-endocrinology at the Univeristy of Texas M.D. Anderson Cancer Center, and co-founder of the ICC, says, "Our hope is that the IOM's findings will reveal new research directions and opportunities, and help overcome research shortcomings of earlier years when minority scientists were only on the fringes of U.S. medicine." The IOM will be reporting their findings back to Congress by January, 1998
Intense lobbying by the Intercultural Cancer Council (ICC) resultedin Congress providing $600,000 for a study on "the statusof research into cancer among minorities and the medically underservedat the National Institutes of Health." The study will becarried out by an advisory committee expected to be establishedin early 1997 by the Institute of Medicine. The committee willexamine a laundry list of issues, some of them already the subjectof analysis by the new NCI office of special populations headedby Otis Brawley, md, an oncologist. Brawley says he is tryingto come up with a research agenda that gets beyond some of themyths that have politicized the cancer field. For example, henotes that contrary to conventional wisdom, blacks in many casesform a disproportionately high percentage of participants in cancertreatment trials. Lovell Jones, phd, director of experimentalgynecology-endocrinology at the Univeristy of Texas M.D. AndersonCancer Center, and co-founder of the ICC, says, "Our hopeis that the IOM's findings will reveal new research directionsand opportunities, and help overcome research shortcomings ofearlier years when minority scientists were only on the fringesof U.S. medicine." The IOM will be reporting their findingsback to Congress by January, 1998.
!["[G]iven the improvements in compliance and tolerability of the de-escalated regimen in older patients, with preserved early cancer outcomes, this reduced-dose regimen could be considered a new treatment option for [patients who are] frailer [and] not fit for standard-dose chemoradiotherapy," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F8987adec8367653dbaf8fc0f82c7dbfcb914281e-500x404.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[G]iven the improvements in compliance and tolerability of the de-escalated regimen in older patients, with preserved early cancer outcomes, this reduced-dose regimen could be considered a new treatment option for [patients who are] frailer [and] not fit for standard-dose chemoradiotherapy,\" according to the study authors.")
